Affiliation: Cross S.A., Via Lavizzari 18, CH-6850 Mendrisio, Switzerland.
Background: The non absorbable antibiotic rifamycin SV newly formulated as modified colonic release MMX® tablets was preliminarily investigated. Methods: In a multi-centre, double-blind, double-dummy, randomised, parallelgroup study, efficacy and safety of the 200 mg tablets were investigated vs. rifaximin 200 mg tablets in infectious diarrhoea. Results: 22 rifamycin SV recipients (47.8%) were successes, whilst 24 (52.5%) discontinued. In the reference group 27 (50.9%) were successes, whilst 26 (49.1%) discontinued. The median time to last unformed stool was 67.5 h after rifamycin SV and 65.5 h after rifaximin. Conclusions: The efficacy of the new tablets was not significantly different from that of rifaximin administered 4 times a day for 3 days. The treatments did not differ in rate or frequency of therapeutic success. Isolates of Campylobacter jejuni and lari, Escherichia coli, Anaerobiospirillum, Salmonella enteritidis and Shigella flexneri found at pre-treatment were not retrievable after rifamycin SV.